热门资讯> 正文
Biogen预计第四季度IPR & D对每股盈利的影响约为1.26美元/股
2026-01-14 19:41
- Biogen (BIIB) expects its Q4 results to include acquired in-process research and development, upfront and milestone expenses of around $222M on a pre-tax basis.
- The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the quarter by around $1.26 per share.
- Analysts expect the firm to earn $1.68 on revenue of $2.21B in Q4.
More on Biogen
- 44th Annual J.P. Morgan Healthcare Conference
- Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
- AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma
- Biogen outlines 67% launch product growth and signals expanded pipeline momentum amid strong Q3 results
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
